Methods and Compositions For Improving Outcomes of Cancer Patients
AssigneeReven IP HoldCo LLC
InventorsJames Ervin, Hendrik J. Van Wyk, Brian D. Denomme, Mariette L. Van Wyk, Peter Pacult, Michael A. Volk, Natalie M. Pizzimenti
Life of this patent
Estimating the term…
Abstract
This disclosure provides compositions and methods for improving outcomes in cancer patients.
Claims45
A method of preventing, alleviating, or treating a hypoxia-related disease or condition, comprising administering an effective amount of a composition to a subject in need thereof to improve oxygen transport and thereby elevate blood oxygen levels, wherein the composition comprises:
- at least one pharmaceutical grade acid and at least one pharmaceutical grade pH buffering agent in a sterile aqueous solution,
- wherein the concentration of the pharmaceutical grade acid and the pharmaceutical grade pH buffering agent in the buffer solution is sufficient to provide a total titratable acid content between 60 mmol/L and 3000 mmol/L when administered to a subject, and
- wherein the selection of the pharmaceutical grade acid and the pharmaceutical grade pH buffering agent is effective to provide a buffer solution pH of between 4.0 and 7.7.
A method of treating a subject suffering from a condition characterized by elevated serum calcium, comprising administering an effective amount of a composition to the subject to reduce blood calcium levels, wherein the composition comprises:
- at least one pharmaceutical grade acid and at least one pharmaceutical grade pH buffering agent in a sterile aqueous solution,
- wherein the concentration of the pharmaceutical grade acid and the pharmaceutical grade pH buffering agent in the buffer solution is sufficient to provide a total titratable acid content between 60 mmol/L and 3000 mmol/L when administered to a subject, and
- wherein the selection of the pharmaceutical grade acid and the pharmaceutical grade pH buffering agent is effective to provide a buffer solution pH of between 4.0 and 7.7.
A method of restoring tumor suppressor protein p53 function in a subject, comprising administering an effective amount of a composition to the subject, wherein the composition comprises:
- at least one pharmaceutical grade acid and at least one pharmaceutical grade pH buffering agent in a sterile aqueous solution,
- wherein the concentration of the pharmaceutical grade acid and the pharmaceutical grade pH buffering agent in the buffer solution is sufficient to provide a total titratable acid content between 60 mmol/L and 3,000 mmol/L when administered to a subject, and
- wherein the selection of the pharmaceutical grade acid and the pharmaceutical grade pH buffering agent is effective to provide a buffer solution pH of between 4.0 and 7.7.
A method of suppressing tumor aggression in a subject having a cancer while restoring angiogenesis in healthy tissue of the subject, comprising administering an effective amount of a composition to the subject to increase eNOS and suppress iNOS, wherein the composition comprises:
- at least one pharmaceutical grade acid and at least one pharmaceutical grade pH buffering agent in a sterile aqueous solution,
- wherein the concentration of the pharmaceutical grade acid and the pharmaceutical grade pH buffering agent in the buffer solution is sufficient to provide a total titratable acid content between 60 mmol/L and 3,000 mmol/L when administered to a subject, and
- wherein the selection of the pharmaceutical grade acid and the pharmaceutical grade pH buffering agent is effective to provide a buffer solution pH of between 4.0 and 7.7.
A method of treating a subject having a cancer and suffering from elevated blood glucose related to the cancer, comprising administering an effective amount of a composition to the subject to improve pituitary, thyroid and renal function, thereby reducing blood glucose levels, wherein the composition comprises:
- at least one pharmaceutical grade acid and at least one pharmaceutical grade pH buffering agent in a sterile aqueous solution,
- wherein the concentration of the pharmaceutical grade acid and the pharmaceutical grade pH buffering agent in the buffer solution is sufficient to provide a total titratable acid content between 60 mmol/L and 3,000 mmol/L when administered to a subject, and
- wherein the selection of the pharmaceutical grade acid and the pharmaceutical grade pH buffering agent is effective to provide a buffer solution pH of between 4.0 and 7.7.
A method of inhibiting poly ADP ribose polymerase (PARP), comprising administering to a subject in need thereof an effective amount of a composition, wherein the composition comprises:
- at least one pharmaceutical grade acid and at least one pharmaceutical grade pH buffering agent in a sterile aqueous solution,
- wherein the concentration of the pharmaceutical grade acid and the pharmaceutical grade pH buffering agent in the buffer solution is sufficient to provide a total titratable acid content between 60 mmol/L and 3,000 mmol/L when administered to a subject, and
- wherein the selection of the pharmaceutical grade acid and the pharmaceutical grade pH buffering agent is effective to provide a buffer solution pH of between 4.0 and 7.7.
A method of restoring a disturbed bone marrow microenvironment, comprising administering an effective amount of a composition to a subject in need thereof, the method comprising:
- at least one pharmaceutical grade acid and at least one pharmaceutical grade pH buffering agent in a sterile aqueous solution,
- wherein the concentration of the pharmaceutical grade acid and the pharmaceutical grade pH buffering agent in the buffer solution is sufficient to provide a total titratable acid content between 60 mmol/L and 3,000 mmol/L when administered to a subject, and
- wherein the selection of the pharmaceutical grade acid and the pharmaceutical grade pH buffering agent is effective to provide a buffer solution pH of between 4.0 and 7.7.
A method of promoting apoptosis in cancer, comprising administering an effective amount of a composition to a subject in need thereof, thereby eliciting a temporarily elevated acidic pH in the bloodstream to further decreasing intracellular pH which results in acidic stress and apoptosis in cancer cells, wherein the composition comprises:
- at least one pharmaceutical grade acid and at least one pharmaceutical grade pH buffering agent in a sterile aqueous solution,
- wherein the concentration of the pharmaceutical grade acid and the pharmaceutical grade pH buffering agent in the buffer solution is sufficient to provide a total titratable acid content between 60 mmol/L and 3,000 mmol/L when administered to a subject, and
- wherein the selection of the pharmaceutical grade acid and the pharmaceutical grade pH buffering agent is effective to provide a buffer solution pH of between 4.0 and 7.7.
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
Dependencies are inferred from the claim text.